Marek Jasiówka

Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

Tomasz Byrski, Tomasz Huzarski, R. Dent et al. · Breast Cancer Research and Treatment · 2014 · 266 citations

Breast Oncology, Pathologic Complete Response, Medicine +9

Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

Matthew J. Ellis, Antonio Llombart‐Cussac, David Feltl et al. · Journal of Clinical Oncology · 2015 · 233 citations · Full text

Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer

DJ Slamon, W. Eiermann, NJ Robert et al. · Cancer Research · 2016 · 149 citations

Breast Oncology, Immunology, Pathology +16

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland

Piotr Wójcik, Marek Jasiówka, E. Strycharz et al. · Hereditary Cancer in Clinical Practice · 2016 · 42 citations · Full text

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer

Alicja Łukomska, Janusz Menkiszak, Jacek Gronwald et al. · Cancers · 2021 · 31 citations · Full text